Literature DB >> 1613441

Enhancement of noradrenaline-induced inositol polyphosphate formation by glucocorticoids in rat vascular smooth muscle cells.

J Liu1, R M Haigh, C T Jones.   

Abstract

Glucocorticoids are known to regulate the contractility of vascular smooth muscle by increasing its response to noradrenaline. The molecular mechanisms for achieving this remain unclear. Recent results in our laboratory have demonstrated that glucocorticoids affect both alpha 1-adrenoceptor number and coupling to G proteins. Whether this leads to an increase in second-messenger production has to be established. The present experiments, therefore, report the effects of dexamethasone on inositol polyphosphate production in vascular smooth muscle cells in culture. Noradrenaline induced the release of inositol polyphosphates from prelabelled [3H]inositol phosphoinositides in the membrane in a dose-dependent manner. The concentration of noradrenaline which caused half-maximal response was 1.26 mumol/l. Prazosin inhibited noradrenaline-induced inositol monophosphate formation to 10.26 +/- 3.67% (mean +/- S.E.M.; P less than 0.01, n = 5) of control value whereas yohimbine reduced it to only 61.74 +/- 11.82% (P less than 0.05, n = 5), suggesting an action primarily through alpha 1-adrenergic receptors. Dexamethasone (100 nmol/l, 48 h) enhanced noradrenaline-induced inositol monophosphate, bisphosphate and trisphosphate formation up to twofold (P less than 0.001, n = 5). The enhancement of the response occurred despite the fact that dexamethasone reduced [3H]inositol prelabelling of membrane phosphoinositides by 49.5 +/- 9.9% (P less than 0.05, n = 3). The present results suggest that the potential action of glucocorticoids on vascular smooth muscle contractility is, at least in part, through controlling alpha 1-adrenoceptor-mediated second-messenger production.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1613441     DOI: 10.1677/joe.0.1330405

Source DB:  PubMed          Journal:  J Endocrinol        ISSN: 0022-0795            Impact factor:   4.286


  5 in total

1.  Effects of low dose dexamethasone treatment on basal cardiovascular and endocrine function in fetal sheep during late gestation.

Authors:  Andrew J W Fletcher; Hugh H G McGarrigle; C Mark B Edwards; Abigail L Fowden; Dino A Giussani
Journal:  J Physiol       Date:  2002-12-01       Impact factor: 5.182

2.  Cardiovascular and endocrine responses to acute hypoxaemia during and following dexamethasone infusion in the ovine fetus.

Authors:  Andrew J W Fletcher; David S Gardner; C Mark B Edwards; Abigail L Fowden; Dino A Giussani
Journal:  J Physiol       Date:  2003-03-28       Impact factor: 5.182

3.  Regulation of histamine H1 receptor coupling by dexamethasone in human cultured airway smooth muscle.

Authors:  E Hardy; M Farahani; I P Hall
Journal:  Br J Pharmacol       Date:  1996-06       Impact factor: 8.739

4.  Dexamethasone in the presence of desipramine enhances MAPK/ERK1/2 signaling possibly via its interference with β-arrestin.

Authors:  Anat Lucki; Ehud Klein; Rachel Karry; Dorit Ben-Shachar
Journal:  J Neural Transm (Vienna)       Date:  2013-10-17       Impact factor: 3.575

Review 5.  The Role of ACTH and Corticosteroids for Sepsis and Septic Shock: An Update.

Authors:  Djillali Annane
Journal:  Front Endocrinol (Lausanne)       Date:  2016-06-20       Impact factor: 5.555

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.